Fig. 2: Effect of treatment with Nivolumab on TruTumor platform at a cohort level. | Nature Communications

Fig. 2: Effect of treatment with Nivolumab on TruTumor platform at a cohort level.

From: Tumor histoculture captures the dynamic interactions between tumor and immune components in response to anti-PD1 in head and neck cancer

Fig. 2

A Heterogenous IFNg release response observed across patients (n = 70 Patient samples) shown as waterfall graph. B Change in CTL proportions (n = 43 Patient samples) and IFNg cytokine secretion (n = 70 Patient samples) in response to treatment. Data is represented as violin plots and p-values calculated using paired t-test C Change in proliferating CTL (CD8 + Ki67 + ) and activated CTL (CD8+GranzymeB + ) on treatment (n = 43 Patient samples). Data is represented as violin plots and p-values calculated using paired t-test D Effect of treatment on total (n = 24 Patient samples) and proliferating (n = 17 Patient samples) CTL/Treg ratio evaluated using flow cytometry. Data is represented as violin plots and p-values calculated using paired t-test. (All paired t-test are performed using Wilcoxon matched-pairs signed rank two tailed test, ****p  <  0.0001) E Differential gene expression (n = 34 Patient samples) analysis upon treatment, compared to control. Highlighted in red are the genes showing a significant over-expression (Wald test p-value < 0.05). Source data are provided as a Source Data file.

Back to article page